| 翻訳と辞書 |
| Michael R. Hayden ： ウィキペディア英語版 |
Michael R. Hayden
Michael Hayden, is a Killam professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine, Hayden is best known for his research in Huntington disease (HD). He is the founder and director of the Centre for Molecular Medicine and Therapeutics in Vancouver, Canada; a genetic research centre within UBC’s Faculty of Medicine and affiliated with the Child & Family Research Institute and the BC Children's Hospital Foundation. He is also the Program Director of the Translational Laboratory in Genetic Medicine in Singapore, and was recently appointed as the President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries
Hayden is the most cited author in the world for HD and ABCA1. In 2010 he was awarded Member of the Order of Canada, following his receipt of the Order of British Columbia in 2009. Hayden received the Canada Gairdner Foundation Wightman Award in 2011, and in 2008 received recognition from the Canadian Institutes of Health Research (CIHR) as Canada's Health Researcher of the Year: CIHR Michael Smith Prizes in Health Research. In addition to his academic work, Hayden is also the founder of three biotechnology companies, NeuroVir, Xenon Genetics Inc. and Aspreva Pharmaceuticals. He is the Chief Scientific Director of Xenon.
== Science ==
Hayden’s research focus is primarily on genetic diseases, including genetics of () disorders, Huntington disease, predictive and personalized medicine. Along with his research team, Hayden has identified 10 disease-causing genes, which includes the identification of the major gene underlying high-density lipoprotein (HDL) in humans. This gene, known as ABCA1, has major implications for atherosclerosis and diabetes. Hayden also identified the first mutations underlying Lipoprotein lipase deficiency (LPL) and developed gene therapy approaches to treat this condition. He is also co-leader of the Canadian Pharmacogenomics Network for Drug Safety project, a BC-led Genome Canada-funded, national strategy to prevent adverse drug reactions.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Michael R. Hayden」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|